Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Superficial Femoral Artery Stenosis
- Sponsor
- Johns Hopkins University
- Enrollment
- 29
- Locations
- 2
- Primary Endpoint
- Patency rate
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This is a prospective randomized controlled trial to compare clinical improvement, cost effectiveness and patency rates between new and improved Nitinol stents and open bypass surgery in the superficial femoral artery disease.
Secondary outcomes also include comparing quality of life, re-intervention rate, mortality, morbidity and time to return to work or regular activities.
Patients with superficial femoral artery lesions will be considered. Patients with TASC II A lesions will not be randomized but treated with PTA/stenting as standard of care. Patients with TASC II B and C lesions will be prospectively randomized into either receiving open bypass or stenting.
Patients with TASC D lesions will be treated with open bypass surgery after angiography.
The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on all enrolled the patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical Inclusion:
- •Must be at least 18 years of age.
- •Patient has been informed of the nature of the study, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Medical Ethics Committee (MEC) of the respective clinical site.
- •Symptomatic patient as evidence by IC or CLI.
- •Patient has failed maximized medical treatment and exercise program.
- •Patient has a resting ABI \< 0.9 or an abnormal exercise ABI if resting ABI is normal.Patient with non-compressible arteries (ABI \> 1.2) must have a TBI \< 0.
- •Patient has a de novo or restenotic lesion(s) with \> 50% stenosis documented angiographically.
- •Patient agrees to return for all required clinical contacts following study enrollment.
- •Patient has no childbearing potential or has a negative pregnancy test within one week prior to the study procedure.
- •Anatomical Inclusion:
Exclusion Criteria
- •Clinical exclusion:
- •Known allergic reaction to anesthesia not able to overcome by medication.
- •Known allergic reaction to contrast not able to overcome by medication.
- •Known history of intolerance to study medicating including ASA, clopidogrel, or ticlopidine.
- •Bleeding disorder or refuses blood transfusion.
- •Prior stenting or bypass of SFA (prior PTA is not an exclusion criteria)
- •Unstable angina, recent MI within a month
- •Malignancy or other condition limiting life expectancy to \< 5 years.
- •Renal insufficiency (serum Cr \> 2.0)
- •Patient has any condition that precludes proper angiographic assessment or makes percutaneous arterial access unsafe (e.g., morbid obesity).
Outcomes
Primary Outcomes
Patency rate
Time Frame: 12 Month Post Operatively
Primary, primary assisted and secondary at 6, 12 month
Clinical improvement
Time Frame: 12 Month Post Operatively
Clinical Improvement is measured as at least 1 Rutherford category
Cost effectiveness
Time Frame: 12 Month Post Operatively
Cost Effectiveness factoring procedure and hospital admission costs
Secondary Outcomes
- Quality of Life improvement(12 Month Post Operatively)
- Re-intervention rate(12 Month Post Operatively)
- 30-day operative mortality(12 Month Post Operatively)
- Morbidity associated with both treatment modalities(12 Month Post Operatively)
- Technical success of both treatment modalities(12 Month Post Operatively)
- Time to return to work and regular activities(12 Month Post Operatively)